Education
About Us
Working with TipRanks
Follow Us
Genor Biopharma Holdings Limited (HK:6998)
:6998
Total Valuation
Genor Biopharma Holdings Limited has a market cap or net worth of HK$5.02B. The enterprise value is HK$158.23M.
Market CapHK$5.02B
Enterprise ValueHK$158.23M
Share Statistics
Genor Biopharma Holdings Limited has 2,011,213,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,011,213,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Genor Biopharma Holdings Limited’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -6.21%.
Return on Equity (ROE)-0.04
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-6.21%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee8.59M
Profits Per Employee-2.14M
Employee Count24
Asset Turnover0.16
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Genor Biopharma Holdings Limited is 56.3. Genor Biopharma Holdings Limited’s PEG ratio is 0.18.
PE Ratio56.3
PS Ratio4.05
PB Ratio0.72
Price to Fair Value0.72
Price to FCF-6.75
Price to Operating Cash Flow-35.83
PEG Ratio0.18
Income Statement
In the last 12 months, Genor Biopharma Holdings Limited had revenue of 206.23M and earned -51.28M in profits. Earnings per share was -0.10.
Revenue206.23M
Gross Profit204.89M
Operating Income-72.55M
Pretax Income-35.13M
Net Income-51.28M
EBITDA-5.15M
Earnings Per Share (EPS)-0.10
Cash Flow
In the last 12 months, operating cash flow was -32.37M and capital expenditures -498.00K, giving a free cash flow of -32.86M billion.
Operating Cash Flow-32.37M
Free Cash Flow-32.86M
Free Cash Flow per Share-0.02
Dividends & Yields
Genor Biopharma Holdings Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.40
52-Week Price Change32.98%
50-Day Moving Average3.06
200-Day Moving Average3.14
Relative Strength Index (RSI)42.29
Average Volume (3m)909.38K
Important Dates
Genor Biopharma Holdings Limited upcoming earnings date is Apr 1, 2026, TBA (Confirmed).
Last Earnings DateAug 29, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
Genor Biopharma Holdings Limited as a current ratio of 8.74, with Debt / Equity ratio of 0.07%
Current Ratio8.74
Quick Ratio8.74
Debt to Market Cap0.00
Net Debt to EBITDA205.41
Interest Coverage Ratio-257.28
Taxes
In the past 12 months, Genor Biopharma Holdings Limited has paid 17.84M in taxes.
Income Tax17.84M
Effective Tax Rate-0.51
Enterprise Valuation
Genor Biopharma Holdings Limited EV to EBITDA ratio is 43.39, with an EV/FCF ratio of 1.81.
EV to Sales-1.08
EV to EBITDA43.39
EV to Free Cash Flow1.81
EV to Operating Cash Flow1.83
Balance Sheet
Genor Biopharma Holdings Limited has HK$1.01B in cash and marketable securities with HK$745.00K in debt, giving a net cash position of HK$1.01B billion.
Cash & Marketable SecuritiesHK$1.01B
Total DebtHK$745.00K
Net CashHK$1.01B
Net Cash Per ShareHK$0.50
Tangible Book Value Per ShareHK$2.05
Margins
Gross margin is 99.56%, with operating margin of -35.18%, and net profit margin of -24.87%.
Gross Margin99.56%
Operating Margin-35.18%
Pretax Margin-17.04%
Net Profit Margin-24.87%
EBITDA Margin-2.50%
EBIT Margin-34.15%
Analyst Forecast
The average price target for Genor Biopharma Holdings Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast1447.56%
EPS Growth Forecast―